NASDAQ:VALN Stock Quote
Valneva SE is a specialty vaccine company focused on developing and commercializing innovative vaccines for infectious diseases
The company is committed to addressing significant unmet medical needs through its diverse pipeline of vaccine candidates, which includes programs for diseases such as Lyme disease and chikungunya. Valneva employs advanced technologies and extensive research to create safe and effective vaccines that aim to improve public health outcomes globally. By collaborating with various health organizations and leveraging its expertise in vaccine development, Valneva seeks to contribute to the prevention of infectious diseases and foster better health through vaccination.
Frequently Asked Questions
How does Valneva SE compare with competitors?
Valneva SE differentiates itself from competitors by focusing on niche markets and developing vaccines for diseases with significant unmet medical needs. The company's innovative approach, combined with its agility in responding to emerging health threats, positions it well against larger, more diversified pharmaceutical firms that may not specialize exclusively in vaccine development.
How does Valneva SE contribute to public health?
Valneva SE contributes to public health by developing vaccines that target infectious diseases, which are critical in preventing outbreaks and promoting community health. By prioritizing research and innovation in vaccine development, Valneva supports global vaccination efforts and aligns with public health goals to reduce disease burden and enhance population immunity.
How does Valneva SE engage with stakeholders?
Valneva SE actively engages with stakeholders through transparent communication, regular updates about its clinical trials, and participation in industry conferences. The company values feedback from investors, healthcare professionals, and regulatory bodies, fostering a collaborative environment that supports its mission to improve global health through innovative vaccines.
What are the company’s growth strategies?
Valneva SE's growth strategies focus on advancing its pipeline of vaccines, expanding its development capabilities, and pursuing strategic partnerships and collaborations. The company aims to leverage its innovative technologies and expertise in order to bring unique vaccines to market, while also exploring various funding opportunities to support research and development efforts.
What are the key milestones for Valneva SE?
Key milestones for Valneva SE include successful clinical trial phases for its vaccine candidates, partnerships with major health organizations, and regulatory approvals. Each milestone signals progress in the company's strategy to bring new vaccines to market, reflecting its ongoing commitment to expand its portfolio and address key health challenges.
What are the risks associated with investing in Valneva SE?
Investing in Valneva SE carries certain risks inherent to the biopharmaceutical industry, including clinical trial failures, regulatory hurdles, and market competition. Market volatility and changes in public health priorities can also impact the company's share performance. Potential investors should conduct thorough research and consider these factors before making investment decisions.
What are Valneva SE's key products?
Valneva SE has several key products in its pipeline and commercial portfolio. Notably, its vaccine for Lyme disease, known as VLA15, aims to provide immunity against this tick-borne illness. Additionally, Valneva developed and received emergency use authorization for its Covid-19 vaccine, VLA2001, underscoring its agility in responding to current global health threats.
What are Valneva SE’s financial performance metrics?
Valneva SE's financial performance metrics typically include revenue growth, research and development expenditures, operational expenses, and profit margins. The company has shown promising growth in its revenue streams, especially during periods of increased demand for its vaccines, reflecting its successful commercialization efforts and strategic initiatives in the biotech sector.
What clinical trials is Valneva SE currently conducting?
Valneva SE is engaged in multiple clinical trials to evaluate its vaccine candidates, including VLA15 for Lyme disease and VLA2001 for Covid-19. These trials are critical for assessing the safety and efficacy of its products, and successful outcomes are expected to lead to regulatory submissions and potential approvals, expanding Valneva's commercial portfolio.
What does Valneva SE do?
Valneva SE is a specialty vaccine company that focuses on developing and commercializing innovative vaccines for infectious diseases. The company aims to address unmet medical needs by leveraging its expertise in vaccine development, production, and commercialization. Valneva's portfolio includes vaccines for diseases such as Lyme disease, Chikungunya, and Covid-19, reflecting its commitment to global health.
What is the science behind Valneva SE’s vaccine technology?
Valneva SE employs innovative vaccine technologies, including inactivated virus and recombinant protein platforms, to develop its vaccine candidates. This scientific approach enables the company to create robust and targeted immune responses, enhancing the efficacy of its vaccines against specific infectious diseases and leveraging established methodologies for safety.
What is the significance of American Depositary Shares (ADS)?
American Depositary Shares (ADS) allow U.S. investors to trade shares in foreign companies, such as Valneva SE, on American stock exchanges like Nasdaq. Each ADS represents a specific number of shares in the underlying company, providing investors access to Valneva's performance and growth potential while simplifying the trading process in U.S. markets.
What is Valneva SE's vision for the future?
Valneva SE envisions a future where its innovative vaccines significantly improve global health outcomes. The company aims to expand its product portfolio while continuing to address emerging health threats. Valneva is dedicated to harnessing its scientific expertise and collaborative partnerships to pioneer vaccine solutions that protect communities worldwide.
What partnerships does Valneva SE have?
Valneva SE has established several strategic partnerships, including collaborations with governmental organizations and other biopharmaceutical companies. These partnerships are aimed at co-developing vaccine candidates, enhancing research capabilities, and facilitating access to funding and resources necessary for advancing Valneva's vaccine pipeline.
What regulatory approvals has Valneva SE received?
Valneva SE has successfully obtained regulatory approvals for its vaccines in various jurisdictions. Notably, its Covid-19 vaccine, VLA2001, received emergency use authorization from multiple health authorities. These approvals reflect the company's commitment to meeting rigorous safety and efficacy standards in the vaccine development process.
When did Valneva SE go public?
Valneva SE went public in 2021 by listing its shares on the Nasdaq under the ticker symbol VALN. This move aimed to expand its investor base and increase visibility in the U.S. market, facilitating access to capital to fund its vaccine development projects and enhance its operational capabilities.
Where is Valneva SE headquartered?
Valneva SE is headquartered in Saint-Herblain, France. The company has a strong presence in Europe and operates globally, with facilities for research, development, and production located in various countries, supporting its mission to produce effective vaccines for worldwide distribution.
Who are the key executives at Valneva SE?
Valneva SE is led by a team of experienced executives, with Thomas Lingelbach serving as the CEO and Franck Grimaud as the President and co-founder. The leadership team consists of professionals with deep expertise in the biopharmaceutical and vaccine industries, guiding the company's strategic direction and operational initiatives.
What is the current price of Valneva SE - American Depositary Shares?
The current price of Valneva SE - American Depositary Shares is 6.920
When was Valneva SE - American Depositary Shares last traded?
The last trade of Valneva SE - American Depositary Shares was at 3:17 pm EDT on April 2nd, 2025